1. United Kingdom Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
NetScientific plc

NetScientific plc

NSCI.L
NetScientific plcGB flagLondon Stock Exchange
53.12
GBp
-0.38
- -
12.72MMarket Cap
NetScientific plc
NSCI.L
(London Stock Exchange)

Recent

price

53.12

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
FRC
- -
- -
- -
- -
- -
0.01
0.1
0.03
0.03
0.09
0.07
0.06
0.05
0.06
Revenue per Share
-0.3
-0.34
-0.4
-2.1
-1.79
-2.84
-2.19
-1.36
-1.1
-0.57
-0.29
-0.13
-0.14
-0.11
Basic EPS, GAAP
-0.1
-0.27
-0.34
-1.91
-1.94
-2.86
-2.59
-1.81
-1.11
-0.53
-0.51
-0.2
-0.12
-0.14
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
-1.13
-2.89
-3.27
-5.71
-6.38
-6.52
-6.27
-6.71
-10.5
-3.35
-2.84
-2.79
Book Value per Share
-0.43
-0.78
-1.19
12.39
5.2
6.42
2.51
1.77
0.81
0.65
0.76
0.86
0.98
0.61
Tangible Book Value per Share
4
4
4
2
4
4
5
6
8
8
6
18
22
24
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
1
- -
- -
1
- -
1
1
1
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
-47,476.19
-2,399.42
-2,413.45
-1,309.8
-472.52
-579.7
-264.95
-433.86
-269.83
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
-1
-1
-1
-4
-6
-11
-11
-8
-8
-4
-2
-2
-3
-3
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
-51,628.57
-2,161.2
-4,864.33
-3,399.18
-611.02
-408.88
-215.45
-308.17
-182.91
Profit Margin (%)
-2
-3
-4
25
16
22
9
7
3
3
1
3
-1
-2
Working Capital
- -
- -
- -
- -
1
- -
- -
- -
- -
- -
- -
1
1
2
LT Debt
-2
-3
-4
25
19
25
13
11
6
5
7
19
25
17
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
9.03%
38.08%
-32.21%
Free Cash Flow
6.12%
-12.49%
21.94%
Net Income, GAAP
5.56%
-9.4%
-14.58%
Sales/Revenue/Turnover
- -
73.84%
43.92%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
1
2022
- -
- -
- -
- -
1
2023
- -
- -
- -
- -
1

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
-0.13
2022
- -
- -
- -
- -
-0.14
2023
- -
- -
- -
- -
-0.11

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
Similar Companies
Genelux Corporation (GNLX)
Pelthos Therapeutics Inc. (PTHS)
Cyxone AB (publ) (CYXO.ST)
Roivant Sciences Ltd. (ROIV)
KemPharm, Inc. (KMPH)
CureVac N.V. (5CV.F)
Business
NetScientific plc (AIM: NSCI.L), now operating as EMV Capital plc following a rebranding in 2025, functions as a deep tech and life sciences venture capital investment group that identifies, invests in, nurtures, and manages high-growth early-stage companies with strong intellectual property; it employs a capital-efficient model combining balance sheet investments, syndicated funding, and funds under management to drive portfolio companies toward value inflection points and exits via M&A, IPOs, or sales to private equity investors. The company provides proactive portfolio management including board representation, fundraising support, IP strategy, corporate collaborations, financial advisory, and executive placements through its in-house team, venture partners, and expert providers; core sectors encompass life sciences focused on diagnostics, therapeutics, digital health, and solutions for healthcare challenges such as oncology, immunotherapy, respiratory monitoring, sepsis detection, and remote patient monitoring; deep tech covering robotics, AI, industrials, electronics, and IoT; and sustainability emphasizing renewable energy, resource efficiency, waste reduction, and sustainable supply chains. Founded in 2012 and headquartered at 20 St Andrew Street, London, United Kingdom, with additional operations in Cambridge, the firm oversees an international portfolio exceeding 70 companies and more than £100 million in assets under management, targeting healthcare systems, B2B industrials, and global innovation markets across the UK, Europe, and the US. Recent developments include the acquisition and integration of Martlet Capital's £23.3 million portfolio and operational business in May 2024 to expand funds under management; a 30% stake investment in Wanda Connected Health Systems in May 2024 for exposure to remote patient monitoring alongside new management and fundraising agreements; fundraisings supporting portfolio firms such as DeepTech Recycling's £2.1 million round in June 2024 (increasing NetScientific's stake to 21.2%), ProAxsis's £1.8 million raise in April 2024, and SageTech Medical's Innovate UK grant win in May 2024; positive clinical milestones for investees like PDS Biotechnology's VERSATILE-002 Phase 2 trial success in May 2024 and Cytovale's sepsis diagnostic validation in May 2024; and the culmination of strategic evolution since acquiring EMV Capital in 2020, marked by the 2025 name change to reflect consolidated operations, portfolio growth from £8 million fair value in 2019, and ambition to reach £200 million AUM.